ArticleAntimicrobial agents and chemotherapy2018
Mutations in
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Current Perspectives onInternational journal of molecular sciences · 2026Review
- Whole-genome and pangenome insights intoPeerJ · 2026Article
- TheMicroorganisms · 2025Review
- Ultra-high field strength electroporation enables efficient DNA transformation and genome editing in nontuberculous mycobacteria.Microbiology spectrum · 2025Article
- Whole-genome phylogenetic analysis ofMicrobiology spectrum · 2025Article
- Durlobactam to boost the clinical utility of standard of care β-lactams againstAntimicrobial agents and chemotherapy · 2025Article
- Diagnosis of nontuberculous mycobacterial infections using genomics and artificial intelligence-machine learning approaches: scope, progress and challenges.Frontiers in microbiology · 2025Review
- Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA ofAntimicrobial agents and chemotherapy · 2024Article
- Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium.Microbiology spectrum · 2023Article
- Article
- Noncanonical Mismatch Repair Protein NucS Modulates the Emergence of Antibiotic Resistance in Mycobacterium abscessus.Microbiology spectrum · 2022Article
- Variability ofAntibiotics (Basel, Switzerland) · 2022Review
- Activity of Tricyclic Pyrrolopyrimidine Gyrase B Inhibitor against Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2022Article
- Epidemiology, Environmental Risks, Virulence, and Resistance Determinants ofFrontiers in microbiology · 2022Article
- High diversity of clinicalFrontiers in public health · 2022Article
- Nontuberculous Mycobacterial Resistance to Antibiotics and Disinfectants: Challenges Still Ahead.BioMed research international · 2022Review
- A Mycobacterium tuberculosis NBTI DNA Gyrase Inhibitor Is Active against Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2021Article
- Current Molecular Therapeutic Agents and Drug Candidates forFrontiers in pharmacology · 2021Review
- Complete Genome Sequence of OvineMicroorganisms · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the frequency of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.